DK2206736T3 - Polyglutamat-aminosyre-konjugater og fremgangsmåder - Google Patents

Polyglutamat-aminosyre-konjugater og fremgangsmåder

Info

Publication number
DK2206736T3
DK2206736T3 DK10004160.7T DK10004160T DK2206736T3 DK 2206736 T3 DK2206736 T3 DK 2206736T3 DK 10004160 T DK10004160 T DK 10004160T DK 2206736 T3 DK2206736 T3 DK 2206736T3
Authority
DK
Denmark
Prior art keywords
methods
amino acid
acid conjugates
polyglutamate
polyglutamate amino
Prior art date
Application number
DK10004160.7T
Other languages
English (en)
Inventor
Lei Yu
Gang Zhao
Sang Van
Zhongling Feng
Xiaoli Fu
Sanjib Kumar Das
Xinghe Wang
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Application granted granted Critical
Publication of DK2206736T3 publication Critical patent/DK2206736T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056Peptides, proteins, polyamino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/14Peptides, e.g. proteins
    • A61K49/146Peptides, e.g. proteins the peptide being a polyamino acid, e.g. poly-lysine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10Alpha-amino-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48Polymers modified by chemical after-treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyamides (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK10004160.7T 2005-12-05 2006-12-01 Polyglutamat-aminosyre-konjugater og fremgangsmåder DK2206736T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74229105P 2005-12-05 2005-12-05
US75791706P 2006-01-10 2006-01-10
US79073506P 2006-04-10 2006-04-10
EP09004686A EP2077290B1 (en) 2005-12-05 2006-12-01 Polyglutamate-amino acid conjugates and methods

Publications (1)

Publication Number Publication Date
DK2206736T3 true DK2206736T3 (da) 2012-04-23

Family

ID=37909775

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10004160.7T DK2206736T3 (da) 2005-12-05 2006-12-01 Polyglutamat-aminosyre-konjugater og fremgangsmåder
DK06838728T DK1969031T3 (da) 2005-12-05 2006-12-01 Polyglutamat-aminosyre-konjugater og fremgangsmåder

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK06838728T DK1969031T3 (da) 2005-12-05 2006-12-01 Polyglutamat-aminosyre-konjugater og fremgangsmåder

Country Status (16)

Country Link
US (2) US20070128118A1 (da)
EP (4) EP2077290B1 (da)
JP (1) JP5237821B2 (da)
KR (1) KR20080074207A (da)
CN (2) CN101321806B (da)
AT (3) ATE432955T1 (da)
AU (1) AU2006322254B2 (da)
BR (1) BRPI0619436A2 (da)
CA (1) CA2631704A1 (da)
DE (2) DE602006007177D1 (da)
DK (2) DK2206736T3 (da)
ES (1) ES2395461T3 (da)
HK (3) HK1124627A1 (da)
RU (1) RU2472812C2 (da)
TW (1) TW200804461A (da)
WO (1) WO2007067417A1 (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
DK2206736T3 (da) 2005-12-05 2012-04-23 Nitto Denko Corp Polyglutamat-aminosyre-konjugater og fremgangsmåder
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
EP2144631A2 (en) * 2007-04-10 2010-01-20 Nitto Denko Corporation Multi-functional polyglutamate drug carriers
FR2915748B1 (fr) * 2007-05-03 2012-10-19 Flamel Tech Sa Acides polyglutamiques fonctionnalises par des groupes cationiques et des groupements hydrophobes et leurs applications, notamment therapeutiques
US20080279782A1 (en) * 2007-05-09 2008-11-13 Nitto Denko Corporation Polymers conjugated with platinum drugs
ES2430380T3 (es) 2007-05-09 2013-11-20 Nitto Denko Corporation Composiciones que incluyen un compuesto hidrófobo y un conjugado de poliaminoácido
WO2008141110A2 (en) * 2007-05-09 2008-11-20 Nitto Denko Corporation Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
JP2008305262A (ja) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc サーバ及びシンクライアント環境でのプリンタ紹介方法
EP2262537A1 (en) * 2008-03-06 2010-12-22 Nitto Denko Corporation Polymer paclitaxel conjugates and methods for treating cancer
EP2151249A1 (en) * 2008-07-28 2010-02-10 Canon Kabushiki Kaisha PH-sensitive probe comprising polymer and fluorescent dye
WO2010014117A1 (en) * 2008-07-30 2010-02-04 Nitto Denko Corporation Drug carriers
CN102196823A (zh) * 2008-09-12 2011-09-21 日东电工株式会社 纤维化疾病的成像剂
US9434610B2 (en) 2008-10-07 2016-09-06 Rexahn Pharmaceuticals, Inc. HPMA—docetaxel conjugates and uses therefore
RU2011117935A (ru) * 2008-10-15 2012-11-27 Нитто Денко Корпорейшн Способ получения конъюгатов полиглутаматов
AU2010306917B2 (en) 2009-10-13 2014-11-27 Rexahn Pharmaceuticals, Inc. Polymeric systems for the delivery of anticancer agents
BR112012022337A2 (pt) * 2010-03-11 2016-07-05 Nitto Denko Corp composição e respectivos método de preparação e uso de quantidade eficaz
CN103204901B (zh) * 2010-05-27 2016-03-09 中国医学科学院药物研究所 紫杉醇共缀物的制备方法
TWI449823B (zh) * 2010-10-04 2014-08-21 Far Eastern New Century Corp Superabsorbent antibacterial fiber and its use
CA2832484A1 (en) * 2011-04-06 2012-10-11 Cedars-Sinai Medical Center Polymalic acid based nanoconjugates for imaging
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
CN102391168B (zh) * 2011-09-16 2013-11-27 中山大学附属第一医院 对称性双功能偶联剂及其偶合分子显像剂
CN102442996B (zh) * 2011-09-16 2014-09-24 中山大学附属第一医院 多胺类小分子显像剂、其生产方法及其应用
ES2677478T3 (es) * 2012-04-12 2018-08-02 Nitto Denko Corporation Conjugados de copolímero
ES2633765T3 (es) * 2012-05-07 2017-09-25 Nitto Denko Corporation Conjugados poliméricos con un ligador
WO2014085471A1 (en) * 2012-11-28 2014-06-05 Prognosdx Health, Inc. Acid-activated compositions for the treatment of cancers, methods of their use and methods of their preparation
US9839694B2 (en) 2013-04-26 2017-12-12 Nitto Denko Corporation Reduction of endotoxins from polyanionic polymer conjugates
US9636411B2 (en) 2013-04-26 2017-05-02 Nitto Denko Corporation Large scale process for preparing poly (glutamyl-glutamate) conjugates
CN103724618B (zh) * 2013-12-03 2016-10-26 江南大学 一种光敏性γ-聚谷氨酸接枝共聚物胶束的制备方法
WO2015129901A1 (ja) * 2014-02-27 2015-09-03 株式会社セルシード アミノ酸誘導体蛍光ポリマー及びそれを利用した蛍光プローブ
AU2014390729B2 (en) * 2014-04-07 2018-11-29 Nitto Denko Corporation Novel polymer-based hydrotropes for hydrophobic drug delivery
EP3238730A4 (en) * 2014-12-26 2018-10-10 Nippon Kayaku Kabushiki Kaisha Pharmaceutical preparation of camptothecin-containing polymer derivative
WO2018222545A1 (en) * 2017-05-27 2018-12-06 Ecovia Renewables Inc. Poly(amino acid) rheology modifier compositions and methods of use
WO2022120147A1 (en) * 2020-12-04 2022-06-09 The Methodist Hospital System Amino acid polymer-platinum anticancer drug conjugates

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA71763B (en) * 1970-04-13 1972-03-29 Lilly Industries Ltd Erythromycylamines via hydrazones
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
JPS60501759A (ja) * 1983-07-01 1985-10-17 バテル メモリアル インステイチユ−ト 生物分解性ポリペプチド及び薬剤の緩慢な放出のためのその使用
US5385738A (en) * 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
EP0179023B1 (fr) 1984-10-19 1991-01-23 Battelle Memorial Institute Polypeptide biodégradable et son utilisation pour le relargage progressif de médicaments
CS254355B1 (en) * 1985-04-10 1988-01-15 Vladimir Saudek Soluble and biodegradatable copolymeres activated for bond of biologicaly active substances
CH667874A5 (fr) * 1985-12-19 1988-11-15 Battelle Memorial Institute Polypeptide synthetique biodegradable et son utilisation pour la preparation de medicaments.
US6673347B1 (en) * 1986-04-30 2004-01-06 Gryphon Therapeutics Polypeptide and protein derivatives and process for their preparation
US5102652A (en) 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
IN165717B (da) * 1986-08-07 1989-12-23 Battelle Memorial Institute
JP2517760B2 (ja) * 1989-05-11 1996-07-24 新技術事業団 水溶性高分子化医薬製剤
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
DK0526503T3 (da) 1990-04-10 1997-10-27 Imarx Pharmaceutical Corp Polymerer som kontrastmedier til magnetisk resonansimagografi
US5219564A (en) * 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
US6517824B1 (en) * 1990-05-14 2003-02-11 University Of Medicine & Denistry Of New Jersey Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
US5372807A (en) 1990-05-14 1994-12-13 University Of Medicine And Dentistry Of New Jersey Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use
US5660822A (en) * 1990-05-14 1997-08-26 University Of Medicine & Dentistry Of N.J. Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use
US6762188B1 (en) * 1990-06-19 2004-07-13 Smithkline Beecham Corporation Pharmaceutically active benzoquinazoline compounds
GB9013615D0 (en) 1990-06-19 1990-08-08 Wellcome Found Pharmaceutical compounds
DE4115789A1 (de) * 1991-05-10 1992-11-12 Schering Ag Makrocyclische polymer-komplexbildner, deren komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
JP2589431B2 (ja) 1991-05-13 1997-03-12 株式会社ディ・ディ・エス研究所 糖修飾ポリグルタミン酸誘導体及びその製造法
GB9120653D0 (en) 1991-09-27 1991-11-06 Procter & Gamble Dispensing agent
US5384333A (en) * 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
KR940003548U (ko) * 1992-08-14 1994-02-21 김형술 세탁물 건조기
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
US6004763A (en) 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
ES2219646T5 (es) * 1993-02-22 2008-11-01 Abraxis Bioscience, Inc. Metodos para la administracion in vivo de compuestos biologicos y composiciones utiles para los mismos.
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5548064A (en) * 1993-05-24 1996-08-20 Biotech Australia Pty Limited Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions
US5449720A (en) * 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers
GB2282384B8 (en) * 1993-08-18 1997-09-04 Europ Economic Community Drug delivery agents incorporating mitomycin
US6441026B1 (en) * 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
US5980862A (en) 1995-06-02 1999-11-09 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
US6713045B1 (en) * 1995-06-02 2004-03-30 Research Corporation Technologies, Inc. Targeted magnetic resonance imaging agents for the detection of physiological processes
US5762909A (en) * 1995-08-31 1998-06-09 General Electric Company Tumor targeting with polymeric molecules having extended conformation
DE19548114C2 (de) * 1995-12-21 2000-04-27 Deutsches Krebsforsch Konjugat, umfassend einen Wirkstoff, ein Polypeptid und einen Polyether
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
PT932399E (pt) * 1996-03-12 2006-05-31 Pg Txl Co Lp Pro-farmacos de paclitaxel hidrossoluveis
US6030941A (en) * 1996-05-01 2000-02-29 Avi Biopharma, Inc. Polymer composition for delivering substances in living organisms
US5929198A (en) 1996-07-16 1999-07-27 Nalco Chemical Company Biodegradable poly (amino acid)s, derivatized amino acid polymers and methods for making same
US5900228A (en) * 1996-07-31 1999-05-04 California Institute Of Technology Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye
US5965118A (en) 1997-04-18 1999-10-12 Access Pharmaceuticals, Inc. Polymer-platinum compounds
AU7124598A (en) 1997-04-18 1998-11-13 Access Pharmaceuticals, Inc. Polymer-platinum compounds
US6251866B1 (en) * 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
US6229009B1 (en) * 1997-08-29 2001-05-08 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Polycarboxylic based cross-linked copolymers
US6528061B1 (en) * 1997-09-04 2003-03-04 Pasteur Institut Immunogenic polypeptides that mimic a surface polysaccharide antigen of a pathogenic microorganism, method for obtaining the same, and their use in vaccine compositions
JP3390965B2 (ja) * 1997-09-12 2003-03-31 理化学研究所 糖結合スフィンゴシンを含有するポリマー化合物
US6391336B1 (en) * 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US20040170563A1 (en) 1997-10-27 2004-09-02 Meade Thomas J. Magnetic resonance imaging agents for the delivery of therapeutic agents
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
AU2795499A (en) 1998-02-26 1999-09-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Conjugated suramin or derivatives thereof with peg, polyaspartate or polyglutamate for cancer treatment
US5981564A (en) 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
US20030124143A1 (en) * 1998-08-31 2003-07-03 Armelle Phalipon Methods for selecting immunogenic polypeptides
US6143817A (en) 1998-10-07 2000-11-07 National Starch & Chemical Co. Use of derivatives of polyamino acids as emulsifiers stabilizers in aqueous free radical emulsion polymerization
AU1688099A (en) * 1998-12-24 2000-07-31 Kyowa Hakko Kogyo Co. Ltd. Pharmaceutical preparation
EP1031354A3 (en) 1999-01-19 2003-02-05 Rohm And Haas Company Polymeric MRI Contrast agents
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20040121954A1 (en) * 1999-04-13 2004-06-24 Xu Wuhan Jingya Poly(dipeptide) as a drug carrier
US20010041189A1 (en) * 1999-04-13 2001-11-15 Jingya Xu Poly(dipeptide) as a drug carrier
WO2000063409A1 (en) 1999-04-21 2000-10-26 Massachusetts Institute Of Technology Endosomolytic agents and cell delivery systems
ES2239602T3 (es) 1999-06-17 2005-10-01 Universiteit Gent Derivados funcionales de poli-alfa-aminoacido utiles para la modificacion de materiales activos biologicamente y su aplicacion.
US6326021B1 (en) 1999-06-18 2001-12-04 The Ohio State University Research Foundation Biocompatible polymeric delivery systems having functional groups attached to the surface thereof
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
WO2001026693A2 (en) 1999-10-12 2001-04-19 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6685915B2 (en) 1999-12-01 2004-02-03 General Electric Company Extended-linear polymeric contrast agents, and synthesizing methods, for medical imaging
US6235264B1 (en) * 1999-12-01 2001-05-22 General Electric Company Medical imaging method for characterizing tumor angiogenesis using polymeric contrast agents
US7166733B2 (en) 2000-01-04 2007-01-23 Access Pharmaceuticals, Inc. O,O'-Amidomalonate and N,O-Amidomalonate platinum complexes
CA2396702C (en) 2000-01-04 2010-03-23 Access Pharmaceuticals, Inc. N,o-amidomalonate platinum complexes
US20020183243A1 (en) 2000-03-17 2002-12-05 Cell Therapeutics, Inc. Polyglutamic acid-camptothecin conjugates and methods of preparation
US20020077290A1 (en) 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
BR0109272A (pt) 2000-03-17 2004-06-29 Cell Therapeutics Inc Agentes conjugados terapêuticos de ácido poliglutâmico, métodos para suas preparações e usos
AU2001244602A1 (en) * 2000-03-30 2001-10-15 Ajinomoto Co. Inc. Drugs retained in target tissue over long time
JP2001288097A (ja) 2000-04-07 2001-10-16 Pg-Txl Co Lp 水溶性パクリタキセル誘導体
CA2411545A1 (en) 2000-06-14 2002-01-03 Medarex, Inc. Tripeptide prodrug compounds
GB0018240D0 (en) 2000-07-25 2000-09-13 Pharmacia & Upjohn Spa Polymeric conjugates of antitumor agents
ES2263659T3 (es) * 2000-09-26 2006-12-16 Toudai Tlo, Ltd. Micela polimerica que contiene cisplatino dentro de ella, y su uso.
WO2002026867A2 (en) * 2000-09-29 2002-04-04 The Regents Of The University Of California Dendrimeric support or carrier macromolecule
US6497901B1 (en) 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds
US7070797B2 (en) * 2000-11-07 2006-07-04 Dana Farber Cancer Institute, Inc. Method of treating hematologic tumors and cancers
US6916492B2 (en) 2001-03-30 2005-07-12 Council Of Scientific & Industrial Research Natural nontoxic multicolor fluorescent protein dye from a marine invertebrate, compositions containing the said dye and its uses
WO2002087497A2 (en) 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
US20030003048A1 (en) 2001-04-26 2003-01-02 Chun Li Diagnostic imaging compositions, their methods of synthesis and use
EP1408066B1 (en) * 2001-06-20 2010-03-31 Nippon Kayaku Kabushiki Kaisha Block copolymer reduced in impurity content; polymeric carrier; pharmaceutical preparations in polymeric form and process for the preparation of the same
US20040043030A1 (en) * 2001-07-31 2004-03-04 Immunomedics, Inc. Polymeric delivery systems
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
US7262164B2 (en) * 2001-11-09 2007-08-28 Enzon, Inc. Polymeric thiol-linked prodrugs employing benzyl elimination systems
US20030109432A1 (en) * 2001-12-10 2003-06-12 Zuo William W. Anticancer polypeptide-metal complexes and compositions, methods of making, and methods of using same
US7261875B2 (en) 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
CN1252130C (zh) 2002-04-01 2006-04-19 北京键凯科技有限公司 亲水性聚合物与丹参酮类药物的结合物以及包含该结合物的药物组合物
US6939538B2 (en) 2002-04-11 2005-09-06 Biomedical Research Models, Inc. Extended release analgesic for pain control
JP2004018494A (ja) 2002-06-19 2004-01-22 Japan Science & Technology Corp ブロック共重合体−薬剤複合体の製造法
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
FR2844514B1 (fr) * 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
DK1580216T3 (da) 2002-10-31 2014-08-18 Nippon Kayaku Kk Derivater med høj molekylvægt af camptotheciner
WO2004099375A2 (en) 2003-04-30 2004-11-18 The General Hospital Corporation Indirectly linked photosensitizer immunoconjugates, processes for the production thereof and methods of use therof
FR2855521B1 (fr) * 2003-05-28 2005-08-05 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
CA2527665A1 (en) * 2003-05-30 2004-12-16 Centocor, Inc. Formation of novel erythropoietin conjugates using transglutaminase
US6855695B2 (en) * 2003-06-13 2005-02-15 Vion Pharmaceuticals, Inc. Water-soluble SHPs as novel alkylating agents
WO2005035003A2 (en) * 2003-09-22 2005-04-21 Dihedron Corporation Compositions and methods for increasing drug efficiency
US20050118718A1 (en) * 2003-09-22 2005-06-02 University Of Utah Research Foundation Stabilization and controlled delivery of ionic biopharmaceuticals
KR100982933B1 (ko) 2003-12-10 2010-09-17 가부시키가이샤 도쿄다이가쿠 티엘오 디아미노시클로헥산 백금 (ⅱ) 과폴리(카르복실산)세그먼트 함유 블록 공중합체의 배위착물, 그 항종양제
US20050152842A1 (en) * 2003-12-24 2005-07-14 Chun Li Poly (L-glutamic acid) paramagnetic material complex and use as a biodegradable MRI contrast agent
WO2005079861A2 (en) 2004-02-13 2005-09-01 Safeway Investments Ltd. Polymeric water soluble prodrugs
EP1722762A2 (en) 2004-03-02 2006-11-22 Massachusetts Institute of Technology Nanocell drug delivery system
US7317070B1 (en) * 2004-03-12 2008-01-08 Sigma-Aldrich Co. Process for the preparation of polyamino acids
CA2562283A1 (en) 2004-04-09 2005-11-24 3M Innovative Properties Company Methods, compositions, and preparations for delivery of immune response modifiers
KR20050104152A (ko) * 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
US20050271585A1 (en) 2004-06-07 2005-12-08 General Electric Company Extended conjugated polymers
US20050276783A1 (en) 2004-06-10 2005-12-15 Ernest Giralt Lledo Polypeptides with the capacity to entrap drugs and release them in a controlled way
CN100475837C (zh) 2004-06-11 2009-04-08 北京键凯科技有限公司 多叉分支的聚乙二醇-氨基酸寡肽及其活性衍生物和药物结合物
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
WO2006041613A2 (en) 2004-10-05 2006-04-20 Nanomega Medical Corporation Nanoparticles for targeting hepatoma cells
CA2583389A1 (en) 2004-10-07 2006-04-20 Emory University Multifunctional nanoparticles conjugates and their use
JP2008522666A (ja) 2004-12-03 2008-07-03 ユニバーシティー オブ ユタ リサーチ ファンデーション 癌のためのmriガイド下光線力学的療法
DK2206736T3 (da) 2005-12-05 2012-04-23 Nitto Denko Corp Polyglutamat-aminosyre-konjugater og fremgangsmåder
US20080051603A1 (en) 2006-06-15 2008-02-28 Cell Therapeutics, Inc. Process for the preparation of poly-alpha-glutamic acid and derivatives thereof
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
EP2144631A2 (en) 2007-04-10 2010-01-20 Nitto Denko Corporation Multi-functional polyglutamate drug carriers
ES2430380T3 (es) 2007-05-09 2013-11-20 Nitto Denko Corporation Composiciones que incluyen un compuesto hidrófobo y un conjugado de poliaminoácido
US20080279782A1 (en) 2007-05-09 2008-11-13 Nitto Denko Corporation Polymers conjugated with platinum drugs
WO2008141110A2 (en) 2007-05-09 2008-11-20 Nitto Denko Corporation Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
EP2262537A1 (en) 2008-03-06 2010-12-22 Nitto Denko Corporation Polymer paclitaxel conjugates and methods for treating cancer
EP2303288A4 (en) 2008-05-22 2015-04-22 Univ Ramot CONJUGATES OF A POLYMER, BISPHOSPHONATE AND ANTI-ANGIOGENESIS AGENT AND USES THEREOF IN THE TREATMENT AND MONITORING OF DISEASES RELATING TO BONES
CN102196823A (zh) 2008-09-12 2011-09-21 日东电工株式会社 纤维化疾病的成像剂
RU2011117935A (ru) 2008-10-15 2012-11-27 Нитто Денко Корпорейшн Способ получения конъюгатов полиглутаматов
WO2011075483A1 (en) 2009-12-16 2011-06-23 Nitto Denko Corporation Controlled synthesis of polyglutamic acid
BR112012022337A2 (pt) 2010-03-11 2016-07-05 Nitto Denko Corp composição e respectivos método de preparação e uso de quantidade eficaz
FR2957692B1 (fr) 2010-03-17 2012-06-08 Delphi Tech Inc Dispositif de commande a commutateur rotatif retro-eclaire par un guide de lumiere
WO2012027204A1 (en) 2010-08-26 2012-03-01 Nitto Denko Corporation End-capped polymers

Also Published As

Publication number Publication date
US9855338B2 (en) 2018-01-02
DK1969031T3 (da) 2009-09-14
CN101321806A (zh) 2008-12-10
CN102125695B (zh) 2014-02-19
JP5237821B2 (ja) 2013-07-17
ATE465205T1 (de) 2010-05-15
EP2206736A1 (en) 2010-07-14
AU2006322254A1 (en) 2007-06-14
EP2206736B1 (en) 2012-02-08
HK1146075A1 (en) 2011-05-13
HK1124627A1 (en) 2009-07-17
RU2472812C2 (ru) 2013-01-20
BRPI0619436A2 (pt) 2011-10-04
ATE432955T1 (de) 2009-06-15
EP2325232A1 (en) 2011-05-25
AU2006322254B2 (en) 2012-08-02
EP1969031A1 (en) 2008-09-17
ATE544802T1 (de) 2012-02-15
EP2077290B1 (en) 2010-04-21
RU2008120699A (ru) 2010-01-20
CA2631704A1 (en) 2007-06-14
WO2007067417A1 (en) 2007-06-14
DE602006007177D1 (de) 2009-07-16
CN102125695A (zh) 2011-07-20
US20170119889A1 (en) 2017-05-04
CN101321806B (zh) 2011-01-26
EP2077290A1 (en) 2009-07-08
HK1135421A1 (en) 2010-06-04
US20070128118A1 (en) 2007-06-07
TW200804461A (en) 2008-01-16
ES2395461T3 (es) 2013-02-12
JP2009518511A (ja) 2009-05-07
DE602006013893D1 (de) 2010-06-02
KR20080074207A (ko) 2008-08-12
EP1969031B1 (en) 2009-06-03

Similar Documents

Publication Publication Date Title
DK2206736T3 (da) Polyglutamat-aminosyre-konjugater og fremgangsmåder
WO2008124735A3 (en) Multi-functional polyglutamate drug carriers
WO2008094834A3 (en) Multi-functional drug carriers
WO2008141110A3 (en) Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
CY1125312T1 (el) Μικροκαψουλες παρατεταμενης αποδεσμευσης με βαση πολυ(λακτιδιο-συν-γλυκολιδιο) που περιεχουν ενα πολυπεπτιδιο και ενα σακχαρο
CY1118120T1 (el) Συνθεσεις βασιζομενες σε πεδιο ινωδονεκτινης τυπου iii, μεθοδοι και χρησεις αυτων
CY1114132T1 (el) Γαστροανθεκτικες φαρμακοτεχνικες μορφες που περιεχουν ριφαξιμινη
DE602007014087D1 (de) Blockcopolymer für wirkstoffkonjugate und deren pharmazeutische zusammensetzungen
CY1115715T1 (el) Διαλυτοποιηση και στοχευομενη χορηγηση δραστικων ουσιων με αυτο-οργανουμενα αμφιφιλα πολυμερη
FI20051203A (fi) Alifaattisiin biohajoaviin välikeosiin perustuvat vapautettavat polymeerikonjugaatit
WO2007127440A3 (en) Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
EA200301250A1 (ru) Фармацевтические композиции, содержащие слаборастворимые и/или чувствительные к кислотам лекарственные средства и нейтрализованные кислотные полимеры
DK1793994T3 (da) Polymælkesyreblæst film og fremgangsmåde til fremstilling deraf
DK1572728T3 (da) Polymerkonjugater med nedsat antigenicitet, fremgangsmåder til fremstilling og anvendelser deraf
DK1543063T3 (da) Medikament levering
ATE540996T1 (de) Polymerbasierter serumalbumin-ersatzstoff
CY1124650T1 (el) Φαρμακευτικο παρασκευασμα που περιεχει ινσουλινη σε κρυσταλλικη μορφη καθως και σε διαλυτοποιημενη μορφη
AR054739A1 (es) Composicion de liberacion sostenida de droga proteica
ATE326968T1 (de) Pharmazeutische zusammensetzung enthaltend tenatoprazol und einen entzündungshemmer
DE60323993D1 (de) Embran aus poly(m-phenylenisophthal-amid)
HUP0500541A2 (hu) Rákellenes antraciklin hatóanyag célterápiára alkalmas pH-érzékeny polimer konjugátjai
DE602006019302D1 (de) Organosilicium-polymer und verfahren zu dessen herstellung
DK1976538T3 (da) Farmaceutisk formulering til behandling af slidgigt indeholdende clodronsyre og hyaluronsyre
WO2007002332A3 (en) Optical imaging contrast agents
DE602007013759D1 (de) Thermoplastische elastomerzusammensetzung, herstellungsverfahren dafür und gegenstände daraus